Your browser doesn't support javascript.
loading
Predicting Toxicity and Response to Pembrolizumab Through Germline Genomic HLA Class 1 Analysis.
Iafolla, Marco A J; Yang, Cindy; Chandran, Vinod; Pintilie, Melania; Li, Quan; Bedard, Philippe L; Hansen, Aaron; Lheureux, Stephanie; Spreafico, Anna; Razak, Albiruni A; Hakgor, Sevan; Giesler, Amanda; Pugh, Trevor J; Siu, Lillian L.
Afiliación
  • Iafolla MAJ; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Yang C; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Chandran V; Krembil Research Institute, University Health Network.
  • Pintilie M; Biostatistics, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Li Q; Faculty of Medicine, Memorial University, St. John's, Newfoundland and Labrador, Canada.
  • Bedard PL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hansen A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Lheureux S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Spreafico A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Razak AA; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Hakgor S; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Giesler A; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
  • Pugh TJ; Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada.
  • Siu LL; Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
JNCI Cancer Spectr ; 5(1)2021 02.
Article en En | MEDLINE | ID: mdl-33554038
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucocitos Mononucleares / Antígenos de Histocompatibilidad Clase I / Linfocitos T CD8-positivos / Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: JNCI Cancer Spectr Año: 2021 Tipo del documento: Article País de afiliación: Canadá
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Leucocitos Mononucleares / Antígenos de Histocompatibilidad Clase I / Linfocitos T CD8-positivos / Anticuerpos Monoclonales Humanizados / Inhibidores de Puntos de Control Inmunológico / Neoplasias Tipo de estudio: Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: JNCI Cancer Spectr Año: 2021 Tipo del documento: Article País de afiliación: Canadá